# A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

> **NCT06764303** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 24 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** NTQ5082 100mg qd
- **DRUG:** NTQ5082 200mg qd

## Key facts

- **NCT ID:** NCT06764303
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2025-07-08
- **Final completion:** 2027-07-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764303, "A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06764303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*